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Background: Aim was to describe the clinical spectrum, therapy, and outcome of ischemic
strokes under therapy with new oral anticoagulants (NOAC).
Methods and results: A literature research was carried out in PubMed. Clinical trials as well as
case reports were included. Four large trials comparing NOAC with warfarin reported 469
ischemic strokes but neither co-medication, nor comorbidities, location, clinical spectrum,
therapy, nor outcome are reported. Eleven cases with ischemic strokes under dabigatran
from the literature are reported. Six patients received thrombolytic therapy, in three of them
unaware dabigatran therapy. Two patients received mechanical recanalization. Two
patients died, one due to cerebral hemorrhage after thrombolysis, the other after partial
recanalization of the basilar artery.
Conclusions: Little is known about ischemic strokes under NOAC. To increase the knowledge,
the data of 469 ischemic strokes which occurred in NOAC-investigating trials should be
analyzed. Furthermore ischemic and bleeding events under NOAC outside clinical trials
should be reported. An international registry, independent from the pharmaceutical indus-
try for collecting these informations is desirable.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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The embolic risk of atrial ﬁbrillation (AF) can be reduced by
vitamin-K-antagonists (VKA) and new oral anticoagulants
(NOAC) like dabigatran, rivaroxaban, and apixaban [1–3].
Nevertheless, these drugs cannot completely abolish the risk
of stroke or embolism. It has been shown that in VKA-treated
AF-patients the strokes are not as severe as in patients
without any anticoagulant therapy [4]. The clinical course of
patients with stroke occurring under NOAC-therapy is largely* Corresponding author at: Steingasse 31/18, A-1030 Wien, Austria. Te
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0028-3843/# 2014 Polish Neurological Society. Published by Elsevier Uunknown and pragmatic approaches have been published for
individualized decision making [5,6]. Thus, aim of the present
article was to describe and discuss the clinical spectrum,
therapy, and outcome of ischemic strokes under NOAC-
therapy.
2. Methods
A literature research was carried out in PubMed using the
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trials as well as case reports in all languages, but no abstracts,
were included. Reference lists and older references generated
from initial papers were also considered. We included only
studies investigating NOAC in patients with atrial ﬁbrillation
and excluded studies in patients with venous thromboembo-
lism. Only studies reporting ischemic strokes but not cerebral
bleeding were considered.
3. Results
3.1. Clinical trials
Four clinical trials were identiﬁed comparing NOAC with VKA
which reported overall 469 ischemic strokes [1–3,7]. The
PETRO-trial studied different dosages of dabigatran in 432
patients during 12 weeks. One patient had a stroke under
50 mg bid dabigatran [7]. In the RE-LY trial the rate of ischemic
stroke was 1.34%/year with 110 mg bid dabigatran and 0.92%/
year with 150 mg bid during a follow-up of 730 days. Overall
270 ischemic strokes occurred under a therapy with dabiga-
tran, 110 mg bid (n = 159) or 150 mg bid (n = 111) [8]. In the
ARISTOTLE-trial,  the rate of ischemic stroke was 1.19%/year
with either 5 or 2.5 mg bid apixaban during a follow-up of 657
days. Overall ischemic strokes occurred in 149 patients under
a therapy with apixaban. It is not indicated how many of the
stroke-patients were assigned to apixaban 5 mg or 2.5 mg bid
[1]. In the ROCKET-AF trial, the rate of stroke or systemic
embolism in the per-protocol population was 1.7%/year with
either 15 or 20 mg rivaroxaban during a follow-up of 707 days.
Overall ischemic strokes occurred in 149 patients under a
therapy with rivaroxaban. It is not indicated how many of the
stroke-patients were assigned to rivaroxaban 20 mg or 15 mg/
d [3]. From these 4 clinical trials neither the co-medication,
comorbidities, location of stroke, clinical manifestations of
the stroke, nor therapy or outcome of ischemic strokes are
reported. Since there are no studies available comparing one
NOAC with the other it is not possible to assess if one of these
drugs is safer and more effective than the other. Caution,
however, is necessary when interpreting the results of the
ARISTOTLE study since 380 patients (2.2%) were lost to follow-
up [1]. Despite the large number of randomized patients in
ARISTOTLE, the absolute difference between the warfarin-
and apixaban-treated patients was only 53 patients regarding
stroke/embolism, 63 regarding death and 70 regarding
intracranial bleeding. Since the number of patients with
missing data was larger than the difference between the
treatment groups, doubts arise about the reliability of
ARISTOTLE. These problems were less frequent in RE-LY
with 0.11% and ROCKET-AF with 0.22% of patients lost to
follow-up.
3.2. Case reports
Additionally, 11 case reports about ischemic strokes, all
occurring under dabigatran were found [9–19]. The clinical
characteristics of these 11 patients are listed in Table 1.
Ischemic strokes occurred in ﬁve female and six male
patients with an age range of 46–89 years. In all of these 11patients, the ischemic stroke was conﬁrmed by computed
tomography; in two patients magnetic resonance imaging was
additionally performed. In one of the 11 patients the ischemic
stroke occurred after electrical cardioversion [11]. In two other
patients the stroke occurred after dabigatran has been
discontinued either for three days because of surgery [9], or
because of skipping one tablet [18]. Stroke etiology was
assessed as cardioembolic in the majority of cases, in one
patient, it was due to dissection of the common and internal
carotid artery [10].
Indication for anticoagulant therapy was atrial ﬁbrilla-
tion in 10 patients, one patient received dabigatran as
prophylaxis for venous thromboembolism after orthopedic
surgery because of a knee prosthesis [12]. Comorbidities are
listed Table 1. One patient suffered simultaneously from
gastrointestinal major bleeding due to non-steroidal-anti-
inﬂammatory-drugs-induced colitis and ischemic stroke
[19].
The comedication was reported in three patients and
comprised acetylsalicylic acid in one [13], digoxin, enalapril,
hydrochlorothiazide in the second [16], and levothyroxine,
dronedarone, nicorandil, furosemide, pantoprazole, atorvas-
tatin, lornoxicam, zolpidem, macrogol, isosorbide mononi-
trate, and alprazolam in the third patient [19]. Four of these
drugs – levothyroxine, dronedarone, pantoprazole, and ator-
vastatin are known to affect the p-glycoprotein activity and
thus may have changed the pharmakokinetics of dabigatran
[20–23].
As expected with dabigatran, routinely performed blood
coagulation tests like international normalized ratio (INR) and
activated partial thromboplastin time (aPTT) were only
slightly abnormal. The lack of typically abnormal coagulation
tests associated with neurologic deﬁcits contributed to
unawareness about dabigatran-medication when deciding
about acute stroke therapy in three cases [12,14,17].
Six patients under dabigatran received thrombolytic
therapy for acute ischemic stroke [10–12,14,17,18]. In three
of these six patients, the physicians were unaware of the
dabigatran therapy [12,14,17]. In awareness of dabigatran, two
further patients received mechanical recanalization, one of
the basilar artery, the other of the middle cerebral artery
[15,16]. The remaining three patients received no speciﬁc
therapy.
Two patients died. One patient died after thrombolysis
due to cerebral hemorrhage who had the shortest interval of
only 370 min between the last dabigatran intake and
thrombolysis [11]. The other patient died after partial
mechanical recanalization of a basilar artery occlusion
without recanalisation [16]. The outcome of the nine
surviving patients is reported as favorable in eight
patients during a follow-up time ranging from 1 to 365 days
(Table 1).
For secondary stroke prevention two patients received
VKA [10,15], one patient received a combination of VKA
and acetylsalicylic acid [13], one patient received dabigatran
[14], and in one patient, any antithrombotic therapy was
contraindicated due to concomitant gastrointestinal bleed-
ing [19]. In the case reports of three further patients, no
information about secondary stroke prevention is given
[9,12,17].
Table 1 – Strokes under dabigatran.
Author Age/sex Dose
of dab
Diagnostic modalities/
stroke location/stroke
severity on admission
Comorbidity Time between
dabigatran intake
and stroke
Coagulation tests Time between
dabigatran intake
and therapy
Aware of NOAC Therapy, outcome
[9] 75/f NI CT, left middle cerebral artery,
NIHSS 8
NI 150 min NI NA Yes No therapy; NIHSS 2
after 24 h
[10] 46/fb NI CT, right middle cerebral artery,
NIHSS 19
NI 150 min aPTT 35 s
(RI 22–34 s)
INR 1.2
(RI 0.8–1.3)
420 min Yes t-PA; NIHSS 12 after
24 h, VKA
[11] 62/m 220 mg CT, left middle cerebral artery,
NIHSS 18
Diab 180 min aPTT 37 s
(RI 24–38)
INR 1.3
(RI 0.7–1.5)
370 min Yes Thrombolysis; lobar
hemorrhage, died
[12] 76/f 220 mg CT, motor aphasia and right
homonymous hemianopsia
NIHSS 4
Hyp, Diab, knee
surgery
780 min aPTT 30.6
INR 1.0
(RI NI)
900 min No t-PA;
asymptomatic after 24 h
[13]a 62/m 300 mg CT and MRI, multiple territories,
thrombus on the valve prosthesis
Mechanical
aortic valve
NI TT > 80 s
(RI 15–20)
aPTT 41 s
(RI 25–37)
NA Yes VKA, ASS; asymptomatic
at 12 month follow-up
[14] 73/m 220 mg CT, right middle cerebral artery,
NIHSS 14
Hyp, TIA 420 min aPTT 38 s
(RI 23–32)
INR 1.1
(RI 0.7–1.5)
NI No 72 mg t-PA, after 7 days
asymptomatic, dabigatran
[15] 76/f 220 mg CT, right middle cerebral artery
NIHSS 18
NI 30 min aPTT 33 s
(RI 24–38 s)
INR 1.3
(RI 0.9–1.2)
285 min Yes Mechanical
recanalization, VKA;
at 3-month modiﬁed
Rankin scale 1
[16]a 78/m 220 mg CT, basilar artery Hyp, recent
vascular surgery
600 min aPTT 33 s
(RI < 33)
INR 2.5
(RI 0.9–1.2)
TT 41 s
(RI 14–21)
660 min Yes Mechanical
recanalization, died
[17] 64/m 300 mg CT, right arm weakness, dysarthria,
left frontal infarct, NIHSS 8
CAD NI INR 1.1
aPTT 38 s
(RI 24–33)
NI No t-PA, further therapy
and outcome NI
[18] 51/m 300 mg CT, right middle cerebral artery,
NIHSS 6
Stroke 950 min INR 1.1
(RI 0.9–1.2)
aPTT 31 s
(RI 23–36)
TT 27 s
(RI 15–21)
1083 min Yes t-PA; at 6-month
modiﬁed Rankin
scale 1; VKA
[19]a 89/f 220 mg CT and MRI, left middle cerebral
artery
CAD, Hyp,
gastrointestinal
bleeding
NI NI NA Yes No therapy;
asymptomatic after
2 weeks
Received dabigatran for prevention of venous thromboembolism after knee operation.
aPTT, activated partial thromboplastin time; CAD, coronary artery disease; Diab, diabetes mellitus; Hyp, hypertension; INR, international normalized ratio; NA, not applicable; NI, not indicated; NIHSS,
The National Institutes of Health Stroke Scale; RI, reference interval; t-PA, recombinant tissue plasminogen activator; TT, thrombin time; VKA, vitamin-K-antagonist.
a Comedication indicated.
b Participant in the RE-LY trial.
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Although the guidelines of several national and international
societies recommend use of NOAC as an alternative to VKA for
prevention of stroke or embolism in AF-patients this review
shows that our knowledge about ischemic strokes occurring
under NOAC is limited to insufﬁciently reported data from
larger studies and a few case reports, all under dabigatran
therapy [24,25]. So far, it is unknown if the clinical presentation
and outcome differs between ischemic strokes under VKA and
NOAC and if there are differences between ischemic strokes
occurring under dabigatran, rivaroxaban, and apixaban. It is
also unknown if comedication with drugs affecting metabo-
lism and pharmacokinetics of NOAC play a role in the
development of ischemic strokes.
The intravenous administration of recombinant tissue
plasminogen activator is the only speciﬁc treatment that
has been approved for acute ischemic stroke with class I
recommendation and evidence level A. Its use is contra-
indicated in patients on VKA with an INR > 1.7 due to the
increased bleeding risk [26]. No recommendation exists about
thrombolytic therapy in acute stroke patients under NOAC.
Clinical decision making in these cases is especially difﬁcult
because no laboratory routine tests are available which
document the anticoagulant activity. This may lead to the
situation that thrombolytic therapy is given, unaware of the
NOAC-therapy, as reported in three single cases (Table 1)
[12,14,17]. Indications for dabigatran-intake in unconscious or
confused patients may be a slightly elevated INR, a prolonged
thrombin time, and a slight prolongation of the activated
partial thromboplastin time, however, as indicated in Table 1,
these ﬁndings are not consistent.
The bleeding risk of thrombolysis in NOAC-treated patients
is unknown. Although we found only one case of a cerebral
hemorrhage after thrombolysis among six dabigatran-treated
patients with ischemic strokes who received thrombolytic
therapy in the literature, the risk may be underestimated
because not all cases are reported and published [11].
5. Conclusion
We conclude that little is known about ischemic strokes under
NOAC, and suggest the following activities:
1. We need the data from the large trials: The clinical implications
and conclusions which can be drawn from the analysis of
only 11 case reports occurring under dabigatran are very
limited. To increase the knowledge, the ischemic strokes
which occurred in NOAC-investigating trials should be
analyzed to get more information about the clinical
spectrum, concomitant medication, therapy, and outcome
of the 469 ischemic events occurring under a therapy of
dabigatran, rivaroxaban or apixaban. This task should be
performed by independent investigators. Since the data are
not published so far it cannot be assessed if the clinical
spectrum, therapy and outcome differed between the
strokes occurring in the NOAC-investigating trials and in
the mentioned 11 case reports.2. Practical recommendations: Unless these data are published
we can only infer from case reports that NOAC intake
should be suspected in any stroke patient especially if
presenting with a history of atrial ﬁbrillation. Laboratory
tests indicating potential NOAC intake may be an elevated
INR, a prolonged activated partial thromboplastin time or
thrombin time. Fatal bleeding occurring in one sixth of the
patients who received thrombolysis under dabigatran is an
argument against thrombolysis. It remains unknown if
patients under NOAC can receive thrombolysis in case of an
acute ischemic stroke or not. There are no data about
thrombolysis in stroke patients receiving apixaban or
rivaroxaban. On the other side, there may be indications
for intravenous or endovascular thrombolytic therapy after
consideration of all pro- and contra arguments and after
informed consent of the patient.
3. Independent registries might be useful: It would be desirable to
establish an international databank, independent from the
pharmaceutical industry, for reporting side effects under
NOAC and to provide hospitals and emergency depart-
ments with easily available laboratory tests to identify
NOAC-use and sufﬁciency of anticoagulation.
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